How Much Does Semaglutide Cost? One Price at Every Dose, Less per Month on a Package

Not at ACT 2. Semaglutide is started at a small dose and increased over the following months on a schedule your clinician sets, and where you end up differs from person to person. The price is the same at every step: the dose is not a pricing axis, so your first month and your twelfth cost the same.

Branded self-pay pricing is often built the other way: Novo Nordisk's self-pay pharmacy, NovoCare, states that its self-pay pricing varies by dose. We do not quote its figures because they change. Compare its current figure for the strength you would start on with the price here before you decide. A flat price means the figure at your first order is the one you can plan the year around.

These figures are for the weekly injection, catalog prices, before the new-patient welcome offer, and they assume twelve continuous months of treatment.

Buying the year as two 6-month packages costs $3,098, against $3,588 paid month by month. Four 3-month packages sit between the two at $3,196.

With the baseline panel. Adding one comprehensive lab panel at the start, and assuming no further panels in the year, the two-package year comes to $3,297. If your clinician asks for repeat testing, each further panel adds $199.

The trade-off. A package is paid up front and commits you to that supply, so starting monthly and moving to a package once the plan has settled is a reasonable pattern. Cancellation terms are shown at checkout. The pricing and insurance FAQ covers how billing works.

ACT 2 is direct-pay and does not bill insurance, Medicare or Medicare Advantage. Whether coverage could get you a branded product for less is a separate question, and sometimes the answer is yes.

Medicare. Medicare Part D excludes drugs "when used for weight loss" by statute. A Part D plan may cover a GLP-1 when it is prescribed for another medically accepted indication, such as type 2 diabetes or reducing the risk of major cardiovascular events in adults with established cardiovascular disease and overweight or obesity. CMS proposed in November 2024 to reinterpret the exclusion so that anti-obesity medications could be covered for obesity, then announced in April 2025 that it was not finalizing that change.

Separately, from July 1, 2026 to December 31, 2027, CMS runs a short-term demonstration, the Medicare GLP-1 Bridge. It gives eligible Part D enrollees certain branded GLP-1 drugs for weight reduction at a fixed monthly copayment, subject to prior authorization and body-mass-index and health-condition criteria, outside the normal Part D benefit. The drugs named are Wegovy, Zepbound KwikPen and Foundayo; compounded semaglutide is not on the list. People with type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease are not eligible, though Medicare notes their Part D plan might cover a GLP-1. If you qualify, that route will usually cost you less out of pocket than any self-pay option, ours included.

Commercial insurance. Coverage varies by plan and by year. A GLP-1 on your plan's formulary is not automatically covered for you: prior authorization and the plan's own criteria sit in between.

The branded route through your own coverage. If your commercial plan covers a branded GLP-1 for you, fill it that way. The Weight Loss Program Membership is $75 a month for the clinical oversight, monitoring and plan review around a branded medication; your own pharmacy bills you for the drug separately.

HSA and FSA. Eligibility is set by your plan administrator and IRS rules, and ACT 2 cannot declare a purchase eligible. FSA and HSA at year-end covers the deadlines.

The semaglutide prescribed through ACT 2 is compounded by a licensed pharmacy. It is not FDA-approved, and it is not the same as, equivalent to or interchangeable with Wegovy, Ozempic or any other branded product. The FDA states that it does not review compounded drugs for safety, effectiveness or quality before they are marketed. Branded semaglutide is FDA-approved and priced by its manufacturer, so the two prices describe two different kinds of product. The compounded semaglutide versus Wegovy page sets out the differences.

• Payment pattern. Monthly, 3-month or 6-month, as in the year table.
• Lab work. $199 per comprehensive panel.
• The welcome offer. New patients get 10% off the first order through the welcome offer. It does not apply to lab panels or to branded medication billed by your own pharmacy.
• Switching medication. Compounded tirzepatide is priced differently; the tirzepatide cost page sets out that arithmetic.

The dose is not on this list, because it does not change the price.